$UTHR News
Last published 2d ago
- 2d agoUTHRUnited Therapeutics Corporation Announces Participation at Upcoming Investor ConferencesBusiness WireSILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update during fireside chat sessions at two upcoming investor conferences in London. UBS Global Biopharma Conference on Monday, November 16, 2026, from 10:00 a.m. to 10:30 a.m., GM ...
- 1w agoUTHRUNITED THERAPEUTICS Corp - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoUTHRUnited Therapeutics Corporation Announces Additional $2 Billion Share Repurchase AuthorizationBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has authorized a new share repurchase program for up to $2 billion of the company’s
- 3w agoUTHRUnited Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026Business WireUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30
- 3w agoUTHRUnited Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production FacilityBusiness WireNamed for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts for its rapidly
- 3w agoUTHRUnited Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPDBusiness WireThe development of a soft mist inhaler (SMI) represents a further advancement of treprostinil delivery devices to potentially address a wider range of patient tolerability profiles A soft mist formulation may be
- 4w agoLQDAUTHRLiquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAHGlobeNewswireFully resolves all six ongoing lawsuits between the companiesMaintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH)Liquidia to pay net $380.7 million in multiple installments
- 4w agoUTHRUnited Therapeutics Presents New Data at the CHEST 2026 Annual MeetingBusiness WireA pre-specified subgroup analysis from the phase 3 ADVANCE OUTCOMES study showed that ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH), regardless of how many
- 1mo agoUTHRUnited Therapeutics Corporation Prevails in Patent Litigation Against LiquidiaBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc.
- 1mo agoUTHRMorgan Stanley 24th Annual Global Healthcare Conference - UNITED THERAPEUTICS CORPEarnings Call TranscriptsAll right. Well, thanks so much for joining us, everybody. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganst
- 2mo agoUTHRUnited Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion AuthorizationBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of its previously announced $2 billion share repurchase authorization. To
- 2mo agoUTHRUnited Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary FibrosisBusiness WireNebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF) if approved by the U.S. Food and Drug Administration
- 2mo agoUTHRUnited Therapeutics Corporation Announces Participation at Upcoming Investor ConferencesBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during fireside chat sessions at four upcoming investor conferences. Martine Rothblatt,
- 2mo agoUTHRUnited Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026Business WireADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients
- 2mo agoUTHRUnited Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial HypertensionBusiness WireRalinepag has the potential to redefine the PAH treatment landscape as the first and only once-daily oral prostacyclin, if approved by the U.S. Food and Drug Administration (FDA) Ralinepag combines potent receptor
- 2mo agoUTHRUnited Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary FibrosisBusiness WireApproximately 200,000 patients in the United States have PPF, with limited treatment options Topline data expected in the second half of 2027 United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment
- 3mo agoUTHRUnited Therapeutics Corporation Reports Second Quarter 2026 Financial ResultsBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2026. Total revenues in the second quarter of 2026 decreased by two
- 3mo agoUTHRUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The LancetBusiness WireThe long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated patients with pulmonary arterial hypertension (PAH) met its primary endpoint and important secondary endpoints with
- 3mo agoUTHRUnited Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of DirectorsBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors appointed Victor Dzau, M.D., to its Board on July 22, 2026.This press release features
- 3mo agoUTHRUnited Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026Business WireUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August 5, 2026, at approximately 6:30
- 4mo agoBETAUTHRBETA Technologies and Multistate Collaborative Complete First Operational Flights of the U.S. DOT and FAA's eVTOL Integration Pilot ProgramBusiness WireThe flights carried manufactured organs, being developed by United Therapeutics The flights are also the first in a series of use cases that will touch at least 26 states nationwide BETA Technologies, Inc. (BETA)
- 4mo agoUTHRUnited Therapeutics Corporation Acquires Thymmune TherapeuticsBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic
- 4mo agoUTHRUnited Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung PerfusionBusiness WireLungFX™ is the first device approved for centralized ex vivo lung perfusion for donor organs not otherwise used for transplant, an important step in advancing United Therapeutics’ platforms United Therapeutics
- 5mo agoLLYBMYMRKPFE+3The space race is coming for pharma: Why drug development is heading to lower Earth orbitCNBCCompanies see a commercial opportunity in creating new ways to administer drugs to patients – in space.
- 5mo agoUTHRUnited Therapeutics Corporation to Present at the Jefferies Global Healthcare ConferenceBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Wednesday, June 3, 2026, from 12:45 to 1:15 p.m.
- 5mo agoUTHRUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026Business WireThe pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF) preserved lung function as measured by absolute forced vital capacity (FVC) and
- 5mo agoUTHRUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026Business WireThe long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening in predominantly pre-treated patients
- 6mo agoUTHRUnited Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical TrialBusiness WireFirst-ever human clinical trial of a xenoheart intended to support potential registration through the submission of a Biologics License Application to the U.S. FDA United Therapeutics Corporation (NASDAQ:UTHR), a
- 6mo agoUTHRVarda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary DiseasePR NewswireVarda Space Industries today announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore the use of microgravity to...
- 6mo agoUTHRUnited Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare ConferenceBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Tuesday, May 19, 2026, from 9:30 to 9:55 a.m. EST,
- 6mo agoUTHRUnited Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026Business WirePresentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF) include efficacy and safety results from TETON-1 and integrated results from
- 6mo agoUTHRUnited Therapeutics Corporation Reports First Quarter 2026 Financial ResultsBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two
- 6mo agoMNKDUTHRMannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung DiseasesGlobeNewswireThe formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPIUnited
- 6mo agoUTHRUnited Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of DirectorsBusiness WireProfessor Dwek's term as a director will conclude at the 2026 Annual Meeting of Shareholders United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the term for Professor
- 6mo agoUTHRUnited Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026Business WireUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2026 financial results in a press release that will be issued on Wednesday, May 6, 2026 at approximately 6:30 a.m.
- 6mo agoUTHRUnited Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026Business WireAn interim analysis of the PHINDER study identifies non-invasive measures that may facilitate earlier detection and management of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD) An interim
- 7mo agoUTHRUnited Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver FailureBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the
- 7mo agoUTHRUnited Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2Business WireNebulized Tyvaso® (treprostinil) Inhalation Solution demonstrated superiority over placebo for the change in absolute forced vital capacity by 130.1 mL and reduced the risk of clinical worsening in patients with
- 8mo agoUTHRUnited Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of MedicineBusiness WireThe pivotal study of Tyvaso® (treprostinil) Inhalation Solution demonstrated a statistically significant preservation of lung function across all subgroups, as measured by absolute forced vital capacity (FVC), and
- 8mo agoUTHRUnited Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase ProgramBusiness WireAgreements for aggregate $1.5 billion Accelerated Share Repurchase (ASR) already executed, with an additional $500 million authorized within the next year United Therapeutics Corporation (Nasdaq: UTHR), a public
- 8mo agoUTHRUnited Therapeutics Corporation to Present at the Leerink Global Healthcare ConferenceBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide a company overview and update on Monday, March 9, 2026, from 1:00 to 1:30
- 8mo agoUTHRUnited Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant EfficacyBusiness WireThe phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint and several important secondary endpoints, including increasing odds of clinical improvement by 47%, in predominantly pre-treated patients with
- 8mo agoUTHRUnited Therapeutics Fourth Quarter/Full Year 2025 Earnings Conference CallUNITED THERAPEUTICS CORPEarnings Call TranscriptsGood morning, everyone, and welcome to the United Therapeutics Corporation 4th Quarter 2025 Corporate Update Conference Call. My name is Jamie, and I will be your conference operator today. All participants on the call p
- 8mo agoUTHRUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18
- 8mo agoUTHRUnited Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care ConferenceBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide a company overview and update on Monday, March 2, 2026, from 2:30 to 3:00 p.m.
- 9mo agoUTHRUnited Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026Business WireUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026. A press release
- 9mo agoUTHRUnited Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver FailureBusiness WireThis study was the world's first FDA-cleared clinical trial using a bioengineered liver. Based on these positive results, United Therapeutics will initiate a phase 2 study Approximately 30% of acute liver failure
- 1y agoUTHRUnited Therapeutics Corporation to Present at Upcoming Investor ConferencesBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming
- 1y agoUTHRUnited Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal DiseaseBusiness WireOngoing EXPAND Study is the First Clinical Trial to Evaluate Xenotransplantation in End-Stage Renal Disease United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its
- 1y agoUTHRUnited Therapeutics Corporation Reports Record Third Quarter 2025 Financial ResultsBusiness WireUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key